Schering's Dermatology business to be called Intendis

10-Sep-2004

Berlin, September 9, 2004 - Schering AG announced today that its new dermatology company will be called "Intendis". The Intendis Group will incorporate Schering AG's world-wide dermatology business and operate its business primarily via own subsidiaries in Europe, Japan and North and South America. On June 15, 2004 Schering announced within the framework of its FOCUS initiative on the new strategic orientation of the Schering Group that it would create a separate legal entity for the company's activities in the field of dermatology.

"We are convinced that an autonomous dermatology business will give us a high degree of flexibility in creating strategic partnerships," said Professor Wolfgang Kehr, Head of Schering's Center of Dermatology and designated Chairman of Intendis' Management Board. "We have a number of successful products such as Finacea®, Advantan® and Psorcutan® Beta and will systematically expand our business. Our aim is to become one of the ten largest pharmaceutical companies world-wide in the field of dermatology by 2010."

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances